Agonist
Back to library
GLP-1Subcutaneous

Mazdutide

Also known as: IBI362 · LY3305677

Dual GLP-1 and glucagon receptor agonist developed for obesity and type 2 diabetes, primarily studied in Chinese populations. Combines GLP-1 satiety with glucagon-driven thermogenesis and hepatic fat reduction.

At a glance

Half-life
5.4 days
Common route
Subcutaneous
Typical dose range
1,500–9,000mcg
Stability (reconstituted)
30days refrigerated

Best timing

Once weekly, consistent day. Side-effect profile similar to other GLP-1/glucagon dual agonists — titrate slowly.

Contraindications

  • Personal or family history of medullary thyroid carcinoma
  • Multiple endocrine neoplasia syndrome type 2
  • History of pancreatitis
  • Severe gastroparesis
  • Pregnancy

Watch symptoms

  • Nausea, vomiting, decreased appetite
  • Diarrhea
  • Resting heart rate increase
  • Hyperglycemia rebound if dose missed
  • Injection site reactions

Citations

The primary literature.

  1. 01Efficacy and safety of mazdutide in Chinese adults with obesity or overweight (Phase 2)PubMed
  2. 02A Phase 1b/2a study of mazdutide in Chinese patients with type 2 diabetesPubMed
Back to library